We, the undersigned 58 organizations, on behalf of millions of patients and American consumers who live with complex conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, multiple sclerosis, and hepatitis, write in response to the Request for Information Regarding Reporting on Pharmacy Benefits and Prescription Drug Costs. The patients we represent rely on prescription drugs to treat their health conditions and prevent others. We are pleased that the Biden administration is moving forward with the requirement that insurance plans must report on various data points associated with prescription drug spending. We believe with this greater understanding and transparency of prescription drug costs, you can better implement policies and measures that increase competition, improve prescription drug affordability and access for the American people.
Support of the PBM Accountability Study Act (HR 1829)
The HIV+Hepatitis Policy Institute strongly supports The PBM Accountability Study Act (HR 1829), which would require the Government Accountability Office to provide a comprehensive report to Congress on the ways in which PBMs influence the pricing of pharmaceuticals, impede competition, use rebates and also provide recommendations on ways to lower prescription drug costs.
Letter to Secretary Becerra about Policies & Solutions to Improve Prescription Drug Affordability for Patients
We, the undersigned 124 organizations, on behalf of millions of patients and American consumers who live with complex conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, multiple sclerosis, and hepatitis, write to congratulate you on becoming Secretary and express our deep commitment and interest in working with you, the Department of Health and Human Services (HHS), and the Biden administration to implement policies and measures that improve prescription drug affordability and access for the American people.
Support of Maryland House Bill 167 so that patients can afford their prescription medications
Comments on additional policy and regulatory revisions in response to the COVID-19 public health emergency
The HIV+Hepatitis Policy Institute, a national, non-profit organization whose mission is to promote quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious…